|The Hemp Report|
|This hemp farm is located in Suffolk, U.K.|
A team of Canadian researchers has sequenced the genome of cannabis sativa, the plant that produces both industrial hemp and marijuana, and in the process they’ve revealed the genetic changes that led to the plant’s drug-producing properties.
A simple genetic switch is likely responsible for the production of THCA, or tetrahyedrocannabinolic acid, the precursor of THC, the active ingredient in marijuana, according to Jon Page, a plant biochemist and adjunct professor of biology at the University of Saskatchewan.
“The transcriptome analysis showed that the THCA synthase gene, an essential enzyme in THCA production, is turned on in marijuana, but switched off in hemp,” Page said.
The team compared the potent Purple Kush marijuana variety with “Finola” hemp, which is grown for seed production, according to Tim Hughes, co-leader of the project and a professor at the Terrence Donnelly Centre for Cellular and Biomolecular Research and the Department of Molecular Genetics at the University of Toronto.
Hemp lacks THCA, but does contain another, non-psychoactive cannabinoid called CBDA, or cannabidiolic acid.
|Horticulture in the Ord Valley|
”Detailed analysis of the two genomes suggests that domestication, cultivation, and breeding of marijuana strains has caused the loss of the enzyme (CBDA synthase), which would otherwise compete for the metabolites used as starting material in THCA production,” Hughes said.
Essentially, this means that over thousands of years of cultivation, hemp farmers selectively bred cannabis sativa into two distinct strains — one for fiber and seed, and one for medicine.
Marijuana has been used medicinally for more than 2,700 years, and continues to be explored for its pharmaceutical potential.
“Plants continue to be a major source of medicines, both as herbal drugs and as pharmaceutical compounds,” Page said. “Although more than 20 plant genomes have been published, ranging from major food crops such as rice and corn, to laboratory models like Arabidopsis, this is the first genome of a medicinal plant.”
The researchers expect that sequencing the cannabis sativa genome will help answer basic questions about the biology of the plant, as well as furthering development of its many applications.
These include strains for pharmaceutical production, high-producing industrial hemp plants, and hemp seed varieties to produce high-quality edible oil. Hemp seed oil is rich in omega 6, an essential fatty acid (EFA), and its fiber is used in the production of textiles.
According to the Canadian Hemp Trade Alliance, about 25,000 acres of hemp were sown in Canada in 2010, much of it in Manitoba. Due to hemp’s association with marijuana, farmers need to be licensed through Health Canada to grow the crop.
Canadian medicinal marijuana is currently produced under Health Canada contract with Prairie Plant Systems, a biotechnology company based in Saskatoon.
The scientific article describing the research findings, “The draft genome and transcriptome of Cannabis sativa,” will be published October 20 in the BioMed Central open access journal Genome Biology available at http://genomebiology.com.